{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:22:44Z","timestamp":1782512564615,"version":"3.54.5"},"reference-count":148,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2000]]},"DOI":"10.1007\/s101560050043","type":"journal-article","created":{"date-parts":[[2002,10,15]],"date-time":"2002-10-15T10:53:15Z","timestamp":1034679195000},"page":"8-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prospects for development of new antimycobacterial drugs"],"prefix":"10.1016","volume":"6","author":[{"given":"Haruaki","family":"Tomioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s101560050043_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0923-2508(93)90023-U","article-title":"Multidrug-resistant tuberculosis and its control","volume":"144","author":"Kochi","year":"1993","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0923-2508(93)90026-X","article-title":"Multiple-drug-resistant tuberculosis: clinical and laboratory issues","volume":"144","author":"McGowan","year":"1993","journal-title":"Res Microbiol"},{"issue":"Suppl 2","key":"10.1007\/s101560050043_bib0015","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1093\/clinids\/17.Supplement_2.S442","article-title":"Drug-resistant tuberculosis","volume":"17","author":"Riley","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s101560050043_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/00222615-44-1-1","article-title":"Tuberculosis into the next centry","volume":"44","author":"Hart","year":"1996","journal-title":"J Med Microbiol"},{"key":"10.1007\/s101560050043_bib0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0923-2508(93)90030-6","article-title":"Treatment and prevention of multidrugresistant tuberculosis","volume":"144","author":"Cohn","year":"1993","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-117-3-177","article-title":"An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection","volume":"117","author":"Fischl","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1007\/s101560050043_bib0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJM199302253280801","article-title":"The emergence of drug-resistant tuberculosis in New York City","volume":"328","author":"Frieden","year":"1993","journal-title":"New Engl J Med"},{"issue":"Suppl","key":"10.1007\/s101560050043_bib0040","doi-asserted-by":"crossref","first-page":"117S","DOI":"10.1378\/chest.87.2_Supplement.117S","article-title":"Standard therapy for tuberculosis 1985","volume":"87","author":"Snider","year":"1985","journal-title":"Chest"},{"key":"10.1007\/s101560050043_bib0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CMR.6.3.266","article-title":"The Mycobacterium avium complex","volume":"6","author":"Inderlied","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"10.1007\/s101560050043_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CMR.9.2.177","article-title":"Epidemiology of infection by nontuberculous mycobacteria","volume":"9","author":"Falkinham","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1007\/s101560050043_bib0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/infdis\/163.6.1326","article-title":"Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution","volume":"163","author":"Ellner","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1007\/s101560050043_bib0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0923-2508(94)90018-3","article-title":"Clinical trials in Mycobacterium avium therapy: lessons to take home","volume":"145","author":"Dauzenberg","year":"1994","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0923-2508(96)80198-7","article-title":"Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective","volume":"147","author":"Benson","year":"1996","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0923-2508(96)80199-9","article-title":"Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex","volume":"147","author":"Reyen","year":"1996","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.28.5.716","article-title":"The fluoroquinolones: pharmacology, clinical uses, and toxicities","volume":"28","author":"Hooper","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.33.1.1","article-title":"Mycobacteria and the new quinolones","volume":"33","author":"Leysen","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0085","first-page":"394","article-title":"New antimycobacterial agents","volume":"51","author":"Yew","year":"1996","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1007\/s101560050043_bib0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/516116","article-title":"The clinical use of fluoroquinolones for the treatment of mycobacterial diseases","volume":"25","author":"Alangaden","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s101560050043_bib0095","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.6.9.1211","article-title":"New drugs for tuberculosis","volume":"6","author":"Grassi","year":"1997","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1007\/s101560050043_bib0100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1128\/AAC.37.6.1259","article-title":"Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin","volume":"37","author":"Tomioka","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0105","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/AAC.38.12.2877","article-title":"In vitro and in vivo antimycobacterial activities of a new quinolone DU-6859a","volume":"38","author":"Saito","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0110","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0115","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.43.12.3001","article-title":"Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"43","author":"Tomioka","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0041-3879(87)90067-5","article-title":"Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"68","author":"Heifets","year":"1987","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/AAC.33.4.591","article-title":"Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin","volume":"33","author":"Gorzynski","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0041-3879(91)90003-B","article-title":"Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria","volume":"72","author":"Tomioka","year":"1991","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/32.6.797","article-title":"In-vitro activities of quinolones against mycobacteria","volume":"32","author":"Garcia-Rodriguez","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0140","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.39.6.1341","article-title":"In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis","volume":"39","author":"Ji","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0962-8479(95)90001-2","article-title":"In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355)","volume":"76","author":"Saito","year":"1995","journal-title":"Tuberc Lung Dis"},{"key":"10.1007\/s101560050043_bib0150","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/AAC.40.3.546","article-title":"Activities of BAY 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice","volume":"40","author":"Bermudez","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0155","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/AAC.40.10.2296","article-title":"Bactericidal action of ofloxacin, sulbactam-ampicilin, rifampin, and isoniazid on logarithmicand stationary-phase cultures of Mycobacterium tuberculosis","volume":"40","author":"Herbert","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002849900095","article-title":"In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages","volume":"33","author":"Rastogi","year":"1996","journal-title":"Curr Microbiol"},{"key":"10.1007\/s101560050043_bib0165","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.40.7.1610","article-title":"In vitro activities of levofloxacin used alone and in combination with first- and secondline antituberculous drugs against Mycobacterium tuberculosis","volume":"40","author":"Rastogi","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0170","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1128\/AAC.40.11.2483","article-title":"Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine","volume":"40","author":"Rastogi","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0962-8479(96)90045-3","article-title":"Combined effect of pyrazinamide and ofloxacin within the human macrophage","volume":"77","author":"Sbarbaro","year":"1996","journal-title":"Tuberc Lug Dis"},{"key":"10.1007\/s101560050043_bib0180","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jac\/40.6.885","article-title":"In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis","volume":"40","author":"Hoffner","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0185","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/AAC.43.3.661","article-title":"Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxy group on survival in liquid media and in human macrophages","volume":"43","author":"Zhao","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0190","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/AAC.43.5.1077","article-title":"In vitro and in vivo antimicrobial activities of T-3811ME, a novel Des-F(6)-quinolone","volume":"43","author":"Takahata","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0195","doi-asserted-by":"crossref","unstructured":"Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of a newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. In press 2000.","DOI":"10.1128\/AAC.44.2.283-286.2000"},{"key":"10.1007\/s101560050043_bib0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.40.3.743","article-title":"In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium","volume":"40","author":"Yajko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0041-3879(91)90025-N","article-title":"Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments","volume":"72","author":"Truffot-Pernot","year":"1991","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.43.1.85","article-title":"Moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0962-8479(96)90070-2","article-title":"Clarithromycin against Mycobacterium avium complex infection","volume":"77","author":"Heifets","year":"1996","journal-title":"Tuberc Lung Dis"},{"key":"10.1007\/s101560050043_bib0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00003495-199754010-00006","article-title":"The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections","volume":"54","author":"Amsden","year":"1997","journal-title":"Drugs"},{"key":"10.1007\/s101560050043_bib0225","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1128\/AAC.33.9.1531","article-title":"In vitro and in vivo activities of clarithromycin against Mycobacterium avium","volume":"33","author":"Fernandes","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0230","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1128\/AAC.33.9.1614","article-title":"In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex","volume":"33","author":"Naik","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0235","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/AAC.35.7.1356","article-title":"Activities of sperfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages","volume":"35","author":"Perronne","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/AAC.36.1.180","article-title":"Activities of four macrolides including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms","volume":"36","author":"Brown","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0245","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/ajrccm\/145.4_Pt_1.856","article-title":"Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium","volume":"145","author":"Heifets","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0250","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.36.8.1695","article-title":"Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium","volume":"36","author":"Heifets","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0255","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.36.9.1987","article-title":"Activities of clarithromycin against slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system","volume":"36","author":"Brown","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0924-8579(94)90006-X","article-title":"In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex","volume":"4","author":"Saito","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s101560050043_bib0265","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1128\/AAC.38.6.1433","article-title":"Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex","volume":"38","author":"Rastogi","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0270","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.39.3.680","article-title":"In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium","volume":"39","author":"Fattorini","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0275","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1128\/AAC.39.4.976","article-title":"Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages","volume":"39","author":"Rastogi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0280","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.39.5.1162","article-title":"In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex","volume":"39","author":"Rastogi","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0285","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1128\/AAC.39.7.1542","article-title":"Synergistic activities of clarithromycin and antituberculous drugs against multidrugresistant Mycobacterium tuberculosis","volume":"39","author":"Cavalieri","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0290","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.39.12.2827","article-title":"Clarithromycin is inactive against Mycobacterium tuberculosis","volume":"39","author":"Truffot-Pernot","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0295","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jac\/37.3.501","article-title":"Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium in human macrophages","volume":"37","author":"Pellegrin","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/41.1.77","article-title":"Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellualr Mycobacterium avium complex phagocytosed by murine peritoneal macrophages","volume":"41","author":"Sato","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jac\/43.3.351","article-title":"Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells","volume":"43","author":"Sato","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0310","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1128\/AAC.36.8.1611","article-title":"Activity of azithromycin against Mycobacterium avium infection in beige mice","volume":"36","author":"Cynamon","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0315","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1128\/AAC.36.11.2413","article-title":"Activity of clarithromycin against Mycobacterium avium complex infection in beige mice","volume":"36","author":"Klemens","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0320","doi-asserted-by":"crossref","unstructured":"Cynamon MH, Klemens SP, Grossi MA. Comparative activities of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 2994;38:1452-4.","DOI":"10.1128\/AAC.38.7.1452"},{"key":"10.1007\/s101560050043_bib0325","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.38.7.1455","article-title":"Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0330","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.38.8.1721","article-title":"Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0335","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/AAC.38.11.2521","article-title":"Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model","volume":"38","author":"Ji","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0340","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.38.12.2717","article-title":"Clarithromycin, dapson, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice","volume":"38","author":"Bermudez","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0345","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/AAC.39.4.878","article-title":"Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL\/6 mice","volume":"39","author":"Struillou","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0350","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1128\/AAC.40.4.1033","article-title":"Roxithromycin alone and in combination with ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice","volume":"40","author":"Bermudez","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0355","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1128\/AAC.41.5.1168","article-title":"Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice","volume":"41","author":"Lounis","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0360","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/AAC.42.3.712","article-title":"Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice","volume":"42","author":"Fattorini","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0365","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/ajrccm\/144.3_Pt_1.564","article-title":"Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial","volume":"144","author":"Dautzenberg","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0370","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0140-6736(91)91965-W","article-title":"Azithromycin for treatment of Mycobacterium avium intracellulare complex infection in patients with AIDS","volume":"338","author":"Young","year":"1991","journal-title":"Lancet"},{"key":"10.1007\/s101560050043_bib0375","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archinte.1993.00410030074010","article-title":"Clarithromycin and other antimycobacterial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome","volume":"153","author":"Dautzenberg","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1007\/s101560050043_bib0380","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, doseranging study in patients with AIDS","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1007\/s101560050043_bib0385","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1164\/ajrccm.153.6.8665032","article-title":"Clarithromycin regimens for pulmonary Mycobacterium avium complex The first 50 patients","volume":"153","author":"Wallace","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1007\/s101560050043_bib0390","first-page":"1","article-title":"The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection","volume":"72","author":"Yamamoto","year":"1997","journal-title":"Kekkaku"},{"key":"10.1007\/s101560050043_bib0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00003495-199754010-00006","article-title":"The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections","volume":"54","author":"Amsden","year":"1997","journal-title":"Drugs"},{"key":"10.1007\/s101560050043_bib0400","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/ajrccm.156.2.atsstatement","article-title":"Diagnosis and treatment of diseases caused by nontuberculous mycobacteria","volume":"156","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1007\/s101560050043_bib0405","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0923-2508(94)90016-7","article-title":"Prevention and treatment of Mycobacterium avium complex infection","volume":"145","author":"Mangura","year":"1994","journal-title":"Res Microbiol"},{"key":"10.1007\/s101560050043_bib0410","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1056\/NEJM199608083350603","article-title":"A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome","volume":"335","author":"Pierce","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1007\/s101560050043_bib0415","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199608083350604","article-title":"Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both","volume":"335","author":"Havlir","year":"1996","journal-title":"New Engl J Med"},{"issue":"Suppl 2","key":"10.1007\/s101560050043_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700542-00003","article-title":"Rationale for the prevention of disseminated Mycobacterium avium complex disease","volume":"54","author":"Dautzenberg","year":"1997","journal-title":"Drugs"},{"key":"10.1007\/s101560050043_bib0425","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1358\/dof.1988.013.09.72694","article-title":"New rifamycins","volume":"13","author":"Traxler","year":"1988","journal-title":"Drugs of the Future"},{"issue":"Suppl 1","key":"10.1007\/s101560050043_bib0430","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s101560050043_bib0435","series-title":"Recent research developments in antimicrobial agents and chemotherapy","first-page":"37","article-title":"In vitro and in vivo antimycobacterial activities of KRM-1648, a new benzoxazinorifamycin","author":"Tomioka","year":"1997"},{"key":"10.1007\/s101560050043_bib0440","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/clinids\/9.3.519","article-title":"Rifabutin (A nsamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases","volume":"9","author":"O'Brien","year":"1987","journal-title":"Rev Infect Dis"},{"issue":"Suppl 1","key":"10.1007\/s101560050043_bib0445","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/clinids\/22.Supplement_1.S37","article-title":"Rifabutin therapy for disseminated Mycobacterium avium complex infection","volume":"22","author":"Sullam","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1007\/s101560050043_bib0450","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/clinids\/22.Supplement_1.S50","article-title":"Use of rifabutin in the treatment of pulmonary tuberculosis","volume":"22","author":"Grassi","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s101560050043_bib0455","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","article-title":"Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Brogden","year":"1994","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1007\/s101560050043_bib0460","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/clinids\/22.Supplement_1.S61","article-title":"Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens","volume":"22","author":"Chaisson","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1007\/s101560050043_bib0465","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/clinids\/22.Supplement_1.S55","article-title":"Prophylaxis for tuberculosis in Europe\u2014ongoing research","volume":"22","author":"Carosi","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s101560050043_bib0470","first-page":"710","article-title":"Determination of in vitro susceptibility of mycobacteria to ansamycin","volume":"132","author":"Heifets","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0475","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0041-3879(87)90026-2","article-title":"In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis","volume":"68","author":"Dickinson","year":"1987","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0480","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/ajrccm\/137.3.719","article-title":"Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis","volume":"137","author":"Heifets","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0485","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0041-3879(88)90020-7","article-title":"Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex","volume":"69","author":"Saito","year":"1988","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0490","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1164\/ajrccm\/141.3.626","article-title":"Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis","volume":"141","author":"Heifets","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0495","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1164\/ajrccm\/145.1.212","article-title":"Activity of rifabutin FCE 22807, rifapentine, and rifampin against Mycobacterium microti and Mycobacterium tuberculosis and their penetration into mouse peritoneal macrophages","volume":"145","author":"Dhillon","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0500","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/ajrccm\/137.3.711","article-title":"Combinations of rifampin or rifabutin plus ethambutol against Mycobacterium avium complex Bactericidal synergistic, and bacteriostatic additive or synergistic effects","volume":"137","author":"Heifets","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0505","first-page":"87","article-title":"In vitro susceptibility of Mycobacterium avium-complex against rifabutin (LM427) alone and in combination with amikacin, roxithromycin and ethambutol","volume":"3","author":"Casal","year":"1990","journal-title":"Rev Esp Quimioterap"},{"key":"10.1007\/s101560050043_bib0510","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm\/136.2.329","article-title":"Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections","volume":"136","author":"Gangadharam","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1007\/s101560050043_bib0515","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.34.9.1629","article-title":"Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized CD4 T-cell-deficient mice","volume":"34","author":"Furney","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0520","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/AAC.35.10.2026","article-title":"In vivo activities of newer rifamycin analogs against Mycobacterium avium infection","volume":"35","author":"Klemens","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0525","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1128\/AAC.37.8.1690","article-title":"Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL\/6 mice with Mycobacterium avium","volume":"37","author":"Lazard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0530","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/AAC.38.2.234","article-title":"Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0535","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.38.10.2346","article-title":"Effectiveness of rifabutin alone or in combination with isoniazid in the preventive therapy of mouse tuberculosis","volume":"38","author":"Jabes","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0540","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.43.10.2356","article-title":"Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice","volume":"43","author":"Lenaerts","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0545","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","article-title":"Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin","volume":"75","author":"Gonzalez-Montaner","year":"1994","journal-title":"Tuberc Lung Dis"},{"key":"10.1007\/s101560050043_bib0550","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/AAC.40.7.1722","article-title":"Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients","volume":"40","author":"Dautzenberg","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/infdis\/155.1.127","article-title":"Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS","volume":"155","author":"Masur","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1007\/s101560050043_bib0560","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/159.4.784","article-title":"Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS","volume":"159","author":"Agins","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1007\/s101560050043_bib0565","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/161.4.801","article-title":"Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients","volume":"161","author":"Hoy","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1007\/s101560050043_bib0570","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0041-3879(91)90002-A","article-title":"Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunistic mycobacteria","volume":"72","author":"Dautzenberg","year":"1991","journal-title":"Tubercle"},{"key":"10.1007\/s101560050043_bib0575","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1007\/s101560050043_bib0580","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1248\/cpb.41.148","article-title":"Synthesis and biological activity of 39-hydroxy-59- aminobenzoxazinorifamycin derivatives","volume":"41","author":"Yamane","year":"1993","journal-title":"Chem Pharm Bull"},{"key":"10.1007\/s101560050043_bib0585","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/AAC.35.3.542","article-title":"In vitro antimycobacterial activity of newly synthesized benzoxazinorifamycins","volume":"35","author":"Saito","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0590","first-page":"67","article-title":"In vitro antimicrobial activity of benzoxazinorifamycin","volume":"37","author":"Tomioka","year":"1993","journal-title":"KRM-1648, against Mycobacterium avium complex determined by radiometric method. Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0595","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1128\/AAC.38.8.1838","article-title":"Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages","volume":"38","author":"Inderlied","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0600","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.39.2.440","article-title":"In vitro activity of benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli","volume":"39","author":"Luna-Herrera","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0605","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/AAC.39.10.2295","article-title":"In vitro and in vivo activities of the benzoxazinorifamycin KRM- 1648 against Mycobacterium tuberculosis","volume":"39","author":"Hirata","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0610","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1128\/AAC.40.6.1482","article-title":"Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages","volume":"40","author":"Mor","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0924-8579(97)00016-2","article-title":"Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis","volume":"8","author":"Dhople","year":"1997","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s101560050043_bib0620","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/AAC.39.7.1489","article-title":"Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648","volume":"39","author":"Fujii","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0625","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"key":"10.1007\/s101560050043_bib0630","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.38.10.2380","article-title":"Characterization of rifampin resistance in pathogenic mycobacteria","volume":"38","author":"Williams","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0635","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.40.11.2655","article-title":"Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampinresistant Mycobacterium tuberculosis isolates with known rpoB mutations","volume":"40","author":"Moghazeh","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0640","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/35.2.345","article-title":"Mutation position and type of substitution in the \u03b2-subunit of the RNA polymerase influence in-vitro activity of rifamycin-resistant Mycobacterium tuberculosis","volume":"35","author":"Bodmer","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s101560050043_bib0645","first-page":"571","article-title":"MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in Mono-Mac-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines","volume":"74","author":"Sato","year":"1999","journal-title":"Kekkaku"},{"key":"10.1007\/s101560050043_bib0650","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1128\/AAC.40.12.2749","article-title":"Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs","volume":"40","author":"Hosoe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0655","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/AAC.36.2.387","article-title":"Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin KRM-1648, against Mycobacterium avium complex infection induced in mice","volume":"36","author":"Tomioka","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0660","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/AAC.37.4.722","article-title":"Therapeutic efficacy of the benzoxazinorifamycin KRM-1648, against experimental Mycobacterium avium infection induced in rabbits","volume":"37","author":"Emori","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0665","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1128\/AAC.38.10.2245","article-title":"Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0670","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.40.2.426","article-title":"In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative KRM-1648, against Mycobacterium tuberculosis","volume":"40","author":"Yamamoto","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0675","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0962-8479(96)90030-1","article-title":"Chemotherapeutic activity of benzoxazinorifamycin KRM-1648, against Mycobacterium tuberculosis","volume":"77","author":"Reddy","year":"1996","journal-title":"Tuberc Lung Dis"},{"key":"10.1007\/s101560050043_bib0680","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","article-title":"Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis","volume":"40","author":"Kelly","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0685","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/AAC.41.2.357","article-title":"Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice","volume":"41","author":"Tomioka","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0690","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0924-8579(98)00010-7","article-title":"Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin KRM- 1648, in SCID mouse model for disseminated Mycobacterium avium complex infection","volume":"10","author":"Emori","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s101560050043_bib0695","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.40.2.298","article-title":"Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model","volume":"40","author":"Klemens","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0700","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/AAC.38.8.1844","article-title":"Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection","volume":"38","author":"Bermudez","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0705","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0962-8479(95)90580-4","article-title":"Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice","volume":"76","author":"Saito","year":"1995","journal-title":"Tuberc Lung Dis"},{"key":"10.1007\/s101560050043_bib0710","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/AAC.40.2.429","article-title":"Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice","volume":"40","author":"Yamamoto","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0715","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0924-8579(98)00078-8","article-title":"Effects of Yokuinin on the therapeutic efficacy of a new benzoxazinorifamycin KRM-1648 against Mycobacterium avium infection","volume":"11","author":"Shimizu","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1007\/s101560050043_bib0720","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1128\/AAC.43.2.360","volume":"43","author":"Sano","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0725","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/AAC.43.3.514","article-title":"Effects of the Chinese traditional medicine Mao-Bushi-Saishin- To on therapeutic efficacy of a new benzoxazinorifamycin KRM- 1648, against Mycobacterium avium infection in mice","volume":"43","author":"Shimizu","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0730","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1128\/AAC.42.10.2674","article-title":"In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains","volume":"42","author":"Oleksijew","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0735","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine is active in vitro and in vivo against Mycobacterium avium complex","volume":"43","author":"Bermudez","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s101560050043_bib0740","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1054\/tuld.1999.0212","article-title":"Antituberculosis activity of certain antifungal and antihelmintic drugs","volume":"79","author":"Sun","year":"1999","journal-title":"Tuberc Lung Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X00713304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X00713304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s101560050043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:42:39Z","timestamp":1761158559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X00713304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000]]}},"alternative-id":["S1341321X00713304"],"URL":"https:\/\/doi.org\/10.1007\/s101560050043","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2000]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospects for development of new antimycobacterial drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s101560050043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}